PeptideDeepDivePeptideDeepDive — Skin & Repair
GHK-Cu Copper Peptide: Evidence, Safety & EU Status
Topical GHK-Cu has some human cosmetic research. However, the evidence is smaller and more mixed than marketing often suggests. By contrast, the injected form has a separate and much thinner safety record.
GHK-Cu: a naturally occurring copper peptide
GHK-Cu is the copper complex of glycyl-L-histidyl-L-lysine, a peptide made from three amino acids. The human body naturally produces it in plasma and other fluids. A research team first isolated GHK from plasma in the 1970s. Because it binds copper ions, many sources call it a copper tripeptide.
Moreover, reviews report that plasma GHK levels tend to fall with age—from about 200 ng/mL around age 20 to about 80 ng/mL by age 60. However, that age-related pattern does not prove that replacing GHK-Cu reverses ageing or treats disease. In fact, a 2020 review noted that researchers had not established a direct link between low serum GHK and specific age-related conditions.
How GHK-Cu works in skin: signalling, collagen and ECM
Instead, studies examine GHK-Cu as a signal rather than as a source of collagen. Lab and animal research links it with swelling, antioxidant activity, tissue repair and the extracellular matrix (ECM), which supports cells.
For example, cell and animal studies suggest effects on collagen, elastin and sugar-based support molecules. Reviews also discuss changes in gene activity. Still, these pathways do not confirm a visible or clinical benefit in people. They explain why teams continue to study the peptide; they do not replace human trials.
Topical vs injectable GHK-Cu: two evidence pictures
The route of use changes the evidence, risks and legal framework. Therefore, do not use findings from topical cosmetics to support claims about injectable GHK-Cu.
Topical cosmetic
For example, some small human studies and older reviews discuss skin appearance. However, the evidence is limited, product-specific and mixed. A compliant finished product must also meet cosmetic safety and claims rules.
Injected / systemic
By contrast, this is not an FDA-approved medicine. Human safety data are limited, while formula quality, sterility, clumping and peptide by-products add separate concerns.
The Key Distinction“Evidence from a topical cosmetic cannot establish the safety or effectiveness of an injectable research product.”
What human evidence exists for topical GHK-Cu?
For example, reviews describe several older, small cosmetic studies that reported changes in skin density, fine lines or skin appearance. Yet many reports provide limited detail and test different formulas. As a result, they do not form a large, modern body of independent trial evidence.
A controlled study found no clear advantage
In a 2006 trial of 40 people after carbon-dioxide laser treatment, the tested copper products did not clearly improve wrinkles or redness compared with controls. Therefore, the human evidence remains mixed rather than settled.
A newer Phase 2 trial has no posted results
A Phase 2 study plans to compare topical GHK-Cu gel with a non-active gel in standard biopsy wounds. The trial record lists a target of 60 people. However, ClinicalTrials.gov currently marks the study status as “Unknown” and shows no results. Therefore, the study cannot yet support wound-healing claims.
GHK-Cu safety: topical irritation vs injectable unknowns
For example, topical cosmetics can cause local irritation or allergy, and safety depends on the complete formula—not only the named peptide. Patch-test findings from one product do not guarantee that every GHK-Cu serum or cream will behave the same way.
Meanwhile, the injected form has much less human safety evidence. FDA materials point to limited human data and possible concerns about immune reactions, clumping and peptide by-products. In addition, poorly controlled supply channels may add sterility, strength and labelling risks.
People with a known copper allergy, copper-metabolism disorder, persistent skin reaction or open wound should seek individual advice from a qualified healthcare professional instead of relying on general online claims.
GHK-Cu regulatory status in the US and Europe
United States: Category 1 is not approval
The FDA has not approved GHK-Cu as a drug. In its 503A categories document updated on 14 May 2026, the agency places non-injectable GHK-Cu in Category 1. In other words, the FDA is still evaluating the nominated substance for possible compounding use. Category 1 does not mean approval or final placement on the 503A bulks list.
The nominators withdrew the injectable route. Separately, the FDA safety page notes limited human evidence and possible peptide-quality concerns. Therefore, the withdrawal does not show that injectable GHK-Cu is safe or authorised.
European Union: topical cosmetics and injections follow different rules
Companies may sell a topical GHK-Cu product as a cosmetic only when the finished product follows the EU Cosmetics Regulation. For example, it needs a responsible person, safety assessment, suitable label and supported cosmetic claims. The ingredient name alone does not make a product compliant.
In contrast, injection is not a cosmetic use. A product presented to treat, prevent or modify disease or physiological functions may fall within medicines law and require the relevant marketing authorization. EU authorities decide borderline classification case by case, based on the product’s composition, presentation, claims and intended use.
The takeaway: GHK-Cu is an active copper peptide with a large body of lab research and some human topical data. Still, the clinical evidence is limited and mixed. The injected form has less evidence, more safety unknowns and a separate legal pathway.
For a wider comparison, see recovery peptides compared, our BPC-157 evidence guide, the TB-500 fragment evidence guide, and research products vs approved medicines explained.
GHK-Cu copper peptide FAQ
What is GHK-Cu?
GHK-Cu is a natural three-amino-acid peptide that binds copper. Studies examine its effects on cell signals, the matrix around cells and skin repair.
Does topical GHK-Cu have human evidence?
Some small human cosmetic studies and older reviews report changes in the skin’s look. However, the clinical evidence is limited and mixed. A controlled study after carbon-dioxide laser treatment found no clear advantage for the tested products. In addition, a newer Phase 2 wound study has no posted results and its current status is unknown.
Is injectable GHK-Cu FDA-approved?
No. The FDA has not approved injected GHK-Cu for any medical use. Its materials also note limited human safety data and possible concerns about immune reactions, clumping and peptide by-products.
What is the current FDA 503A status of GHK-Cu?
As of 14 May 2026, FDA lists GHK-Cu except injectable routes in Category 1, meaning it is under evaluation for the 503A bulks list. Category 1 does not mean FDA approval or final inclusion. The injectable nomination was withdrawn.
Is GHK-Cu legal in Europe?
A topical product may be marketed as a cosmetic in the EU only when the finished product, safety assessment, responsible-person duties, labelling and claims comply with the EU Cosmetics Regulation. Injection is not a cosmetic use. A product presented as a medicine requires the relevant marketing authorization.
How this guide was reviewed
PeptideDeepDive checked the article against PubMed reviews, a controlled human study, ClinicalTrials.gov, current FDA pharmacy-mixing materials and EU law. Add a named, qualified medical reviewer before displaying a “medically reviewed” claim.
References
- Pickart, L. and Margolina, A. (2018). “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” International Journal of Molecular Sciences, 19(7), 1987. PubMed.
- Pickart, L. et al. (2020). “The potential of GHK as an anti-aging peptide.” Biomedical Dermatology. Full text.
- Miller, K. H. et al. (2006). “A randomized clinical trial of copper tripeptide after carbon dioxide laser resurfacing.” Archives of Facial Plastic Surgery. PubMed.
- ClinicalTrials.gov (2026). “GHK-Cu Gel for Acute Cutaneous Wounds,” NCT07437586. Recruitment status listed as unknown; no results posted at the time of review. Trial record.
- U.S. Food and Drug Administration (updated 14 May 2026). “503A Categories Update for September 2024.” FDA document.
- U.S. Food and Drug Administration. “Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.” FDA safety information.
- European Union. Regulation (EC) No 1223/2009 on cosmetic products, consolidated text. EUR-Lex.
- European Commission. “Borderline products” and guidance on the boundary between cosmetics and other regulated products. European Commission.